ANI Pharmaceuticals, Inc.ANIP

Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · United States · anipharmaceuticals.com

ANI Pharmaceuticals is a diversified biopharmaceutical company that develops, manufactures, and commercializes therapeutics through its Rare Disease business (novel products in ophthalmology, rheumatology, nephrology, neurology, and pulmonology), a U.S.-based Generics business, and an Established Brands portfolio. It also operates as a contract development and manufacturing organization (CDMO) for pharmaceutical products. The company is headquartered in Baudette, Minnesota.

Key ratios

Operating cash flow growth

36.2%TTM

2025 189.3%2024 -46.2%

FCF / Sales

17.7%TTM

2025 19.4%2024 7.8%2023 22.6%

Net margin

11.1%TTM

2025 8.9%2024 -3.0%2023 3.9%

ROA

5.5%TTM

2025 3.8%2024 1.9%2023 3.7%

ROE

20.5%TTM

2025 16.2%2024 -4.2%2023 4.7%

Revenue growth

30.9%TTM

2025 43.8%2024 26.2%2023 53.9%

Recent news

ANI Pharmaceuticals to Present at September Investor Conferences 2026-09-03 · GlobeNewswire ANI Pharmaceuticals Appoints Henry Gosebruch to Board of Directors 2026-08-24 · GlobeNewswire ANI Pharmaceuticals Reports Record Second Quarter 2026 Financial Results 2026-08-07 · GlobeNewswire ANI Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 7, 2026 at 8:00 a.m. ET 2026-07-24 · GlobeNewswire

Track ANIP in your journal

Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.

Create a free account

Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer